Skip to main content
SpringerLink
Log in

Extrapyramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie

  • Chapter
Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin

  • 94 Accesses

Zusammenfassung

In den Zeiten, als nur die klassischen Neuroleptika zur Verfügung standen, galten die unerwünschten extrapyramidal-motorischen Begleitwirkungen als größtes Problem der Therapie mit Neuroleptika (Möller et al., 2001; Möller und Schmauss, 1996). Jede dieser Störungen hatte unterschiedliche psychosoziale Konsequenzen für den Patienten. Während z.B. die Frühdyskinesien den Patienten hochgradig ängstigen und ggf. psychotisch interpretiert werden, führt die Akathisie zu einer meist mehrere Tage dauernden motorischen Unruhe mit dem gleichzeitigen Gefühl der inneren Unruhe, das oft schwer von der psychotischen Agitiertheit abzugrenzen ist. Das mehrere Wochen dauernde Parkinsonoid bedeutet eine Veränderung des gesamten Erscheinungsbildes eines Menschen, in schweren Fällen eine Stigmatisierung im Sinne von masken- oder roboterartigem Aussehen. Die Spätdyskinesien wiederum führen zu oft jahrelangen chronischen, auch noch nach Absetzen der Neuroleptika persistierenden leichten bis schweren motorischen Auffälligkeiten mit den daraus folgenden psychosozialen Konsequenzen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • APA. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. Am J Psychiatry 1980; 137: 10.

    Google Scholar 

  • Arana GW, Goff DC, Baldessarini RJ, Keepers GA. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. AM J Psychiatry 1988; 145: 993–996.

    Google Scholar 

  • Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–246.

    Article  Google Scholar 

  • Barnes TR, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874–878.

    Article  Google Scholar 

  • Bartels M, Heide K, Mann K, Schied HW. Treatment of akathisia with lorazepam. An open clinical trial. Pharmacopsychiatry 1987; 20: 51 - 53.

    Article  Google Scholar 

  • Bottlender R, Jäger M, Hofschuster E, Dobmeier P, Möller HJ. Neuroleptic malignant syndrome due to atypical neuroleptics: -three episodes in one patient. Pharmacopsychiatry 2002; 35: 119–121.

    Article  Google Scholar 

  • Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983; 143: 139 - 150.

    Article  Google Scholar 

  • Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ (eds). Drug-induced movement disorders. Futura: New York 1992, 191.

    Google Scholar 

  • Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335 - 46.

    Google Scholar 

  • Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989; 4: 157–175.

    Article  Google Scholar 

  • Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109–120.

    Article  Google Scholar 

  • Cooper SJ, Raniwalla J, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Eur Neuropsychopharmacol 1996; 6 (Suppl 3): 148.

    Article  Google Scholar 

  • Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16–22.

    Article  Google Scholar 

  • Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, Kane JM. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 1989; 25: 222–226.

    Google Scholar 

  • Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990; 81: 3–5.

    Article  Google Scholar 

  • Gardos G. Are antipsychotic drugs interchangeable? J Nerv Ment Dis 1974; 159: 343–348.

    Article  Google Scholar 

  • Gardos G, Cole JO, Salomon M, Schniebolk S. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987; 144: 895–902.

    Google Scholar 

  • Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376.

    Article  Google Scholar 

  • Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatr Scand 1988; 77: 369–378.

    Article  Google Scholar 

  • Gibb WR, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 1986; 49: 861–866.

    Article  Google Scholar 

  • Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S. Neuroleptic Malignant Syndrome: Successful treatment with dantrolene and bromocriptine. Ann Neurol 1983; 14: 89–90.

    Article  Google Scholar 

  • Greil W et al. Untersuchungen zur Entstehung und Behandlung von Spätdyskinesie. In: Hippius H, Rüther E, Schmauss M (eds). Katatone und dyskinetische Syndrome. Springer: Berlin 1989, 213–223.

    Chapter  Google Scholar 

  • Gualtieri CT, Quade D, Hicks RE, Mayo JP, Schroeder SR. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984; 141: 20–23.

    Google Scholar 

  • Haase HJ. Therapie mit Psychopharmaka und anderen seelisches Befinden beeinflussenden Medikamenten. Schattauer: Stuttgart 1982.

    Google Scholar 

  • Hermesh H, Aizenberg D, Weizman A, Lapidot M, Mayor C, Munitz H. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients [see comments]. Br J Psychiatry 1992; 161: 254–257.

    Article  Google Scholar 

  • Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treat¬ments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988; 8: 38S–48S.

    Article  Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozaril collaborative study group: Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.

    Article  Google Scholar 

  • Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40: 893–896.

    Article  Google Scholar 

  • Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473–481.

    Article  Google Scholar 

  • Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254–258.

    Google Scholar 

  • Kasper S, Tauscher J, HEIDEN A. Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 2001; 11 Suppl 4: S405–S413.

    Google Scholar 

  • Keck PE, Jr., Pope HG, Jr., McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991; 148: 880–882.

    Google Scholar 

  • Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68.

    Article  Google Scholar 

  • Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180–190.

    Article  Google Scholar 

  • Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137–1145.

    Google Scholar 

  • Lew TY, Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1983; 18: 1441–1446.

    Google Scholar 

  • Lieberman JA. Neuroleptic-induced movement disorders and experience with clozapine in tardive dyskinesia. J Clin Psychiatry 1990; 8: 3–8.

    Google Scholar 

  • Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–835.

    Google Scholar 

  • Marsden CD. Is tardive dyskinesia a unique disorder? In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds). Dyskinesia - research and treatment. Springer: Berlin, Heidelberg, New York 1985, 64–71.

    Google Scholar 

  • Modestin J, Toffler G, Drescher JP. Neuroleptic malignant syndrome: results of a prospective study. Psychiatry Res 1992; 44: 251 - 256.

    Article  Google Scholar 

  • Möller HJ. Zur Differentialdiagnostik und Therapie katatoner Syndrome unter besonderer Berücksichtigung der febrilen Katatonie. In: Möller HJ, Przuntek H (eds). Therapie im Grenzgebiet von Psychiatrie und Neurologie. Springer: Berlin, Heidelberg, New York 1993, 97–105.

    Google Scholar 

  • Möller HJ. Extrapyramidal side effects of neuroleptic medication: focus on risperidone. In: Brunello N, Racagni G, Langer SZ, Mendlewicz J (eds). Critical issues in the treatment of schizophrenia. Int. Acad. Biomed. Drug Res., Vol. 10. Karger: Basel 1995, 142–151.

    Google Scholar 

  • Möller HJ. Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 2000a; 71: 329–344.

    Article  Google Scholar 

  • Möller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 2000b; 1: 75–91.

    Article  Google Scholar 

  • Möller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000c; 1: 204–214.

    Article  Google Scholar 

  • Möller HJ. Der Einsatz neuer Antipsychotika in der Langzeittherapie der Schizophrenie. In: Möller HJ, Müller N (eds). Schizophrenie: Langzeitverlauf und Langzeittherapie. Springer: Wien. In Druck.

    Google Scholar 

  • Möller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45–49.

    Article  Google Scholar 

  • Möller HJ, Müller WE, Bandelow B. Neuroleptika. Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen. Wissenschaftliche Verlagsgesellschaft: Stuttgart 2001.

    Google Scholar 

  • Möller HJ, Schmauss M. Arzneimitteltherapie in der Psychiatrie. Wissenschaftliche Verlagsgesellschaft: Stuttgart 1996.

    Google Scholar 

  • Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant Syndrome. Successful treatment with bromocriptine. JAMA 1983; 249: 386–388.

    Article  Google Scholar 

  • Owens DGC, Johnstone EC, Frith C. Spontaneous involuntary disorders of movement. Arch Gen Psychiatry 1982; 39: 452–461.

    Article  Google Scholar 

  • Putten T Van. The many faces of akathisia. Compr Psychiatry 1975; 16: 43–47.

    Article  Google Scholar 

  • Putten T Van, May PR, Marder SR. Response to antipsychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry 1984; 141: 16–19.

    Google Scholar 

  • Rak IW, Gorman AP. Maintenance of long-term efficacy with ‘Seroquel’ (quetiapine). Int J Neuropsychopharmacol 2000; 3 (Suppl 1): S149.

    Google Scholar 

  • Rietschel M, Laux G, Möller HJ. Perazin bei neuroleptikabedingter Akathisie. Psychopharmakotherapie 1996; 3: 184 - 190.

    Google Scholar 

  • Sachdev P, Loneragan C. The present status of akathisia. J Nerv MentDis 1991; 179: 381 - 391.

    Article  Google Scholar 

  • Sass H. Probleme der Katatonieforschung. Nervenarzt 1981; 52: 373 - 382.

    Google Scholar 

  • Scheftner WA, Shulman RB. Treatment choice in neuroleptic malignant syndrome. Convulsive Therapy 1992; 8: 267 - 279.

    Google Scholar 

  • Schröder J, Linge C, Wähner A. Zur Differentialdiagnose der malignen Hyperthermie, der febrilen Katatonie und des neuroleptischen malignen Syndroms. Fortschr Neurol Psychiatr 1988; 56: 97–101.

    Article  Google Scholar 

  • Spiess-Kiefer C, Hippius H. Malignant neuroleptic syndrome and malignant hyperthermia - a comparison. Fortschr Neurol Psychiatr 1986; 54: 158–170.

    Article  Google Scholar 

  • Swett C, JR. Drug-induced dystonia. Am J Psychiatry 1975; 132: 532–534.

    Google Scholar 

  • Toenniessen LM, Casey DE, McFarland BH. Tardive dyskinesia in the aged. Duration of treatment relationships. Arch Gen Psychiatry 1985; 42: 278–284.

    Article  Google Scholar 

  • Tune L, Coyle JT. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology (Berl) 1981; 75: 9–15.

    Article  Google Scholar 

  • Varga E, Sugerman AA, Varga V, Zomorodi A, Zomorodi W, Menken M. Prevalence of spontaneous oral dyskinesia in the elderly. AM J Psychiatry 1982; 139: 329–331.

    Google Scholar 

  • Waddington JL. Faktoren der Vulnerabilität für Bewegungsstörungen (Spätdyskinesien) bei der Schizophrenie. In: Hinterhuber H, Kulhanek F, Fleischhacker WW (Hrsg.) Kombination therapeutischer Strategien bei schizophrenen Erkrankungen. Vieweg: Wiesbaden 1990, 194–200.

    Google Scholar 

  • Whitworth AB, Fleischhacker WW. Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 1995; 9 Suppl 5: 21–27.

    Google Scholar 

  • World Health Organisation. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990; 156: 412.

    Article  Google Scholar 

  • Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782–791.

    Google Scholar 

  • Zubenko G, Pope HG, Jr. Management of a case of neuroleptic malignant syndrome with bromocriptine. Am J Psychiatry 1983; 140: 1619–1620. Literatur

    Google Scholar 

  • Ebert D. Quetiapin - ein neues atypisches Neuroleptikum. Fundamentum Psychiatricum 1997; 11: 79–84.

    Google Scholar 

  • Goldstein D. Quetiapin, an Atypical Antipsychotic. Pharmacotherapy 1999; 18: 1183 - 1194.

    Google Scholar 

  • Gunasekara NS, Sencer CM. Quetiapin. A Review of its Use in Schizophrenia. CNS Drugs 1998; 9: 325–340.

    Article  Google Scholar 

  • Hummer M, Fleischhacker WW. Compliance and outcome of patients treated with antipsychotics: the impact of EPS. CNS Drugs 1996; 5: Suppl 1, 13–20.

    Article  Google Scholar 

Download references

Authors
  1. Hans-Jürgen Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Krankenhauses für Psychiatrie und Psychotherapie, Schloss Werneck, Balthasar-Neumann-Platz 1, 97440, Werneck, Deutschland

    Hans-Peter Volz (Chefarzt) (Chefarzt)

  2. Klinischen Abt. für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie Wien, Währinger Gürtel 18-20, A-1090, Wien, Austria

    Siegfried Kasper (Leiter) (Leiter)

  3. Psychiatrische Universitätsklinik Klinik und Poliklinik für Psychiatrie und Psychotherapie, LMU, Nussbaumstraße 7, 80336, München, Deutschland

    Hans-Jürgen Möller (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 DUV/GWV Fachverlage GmbH, Wiesbaden

About this chapter

Cite this chapter

Möller, HJ. (2004). Extrapyramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie. In: Volz, HP., Kasper, S., Möller, HJ. (eds) Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin. Deutscher Universitätsverlag. https://doi.org/10.1007/978-3-322-83447-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-322-83447-8_2

  • Publisher Name: Deutscher Universitätsverlag

  • Print ISBN: 978-3-8244-2174-9

  • Online ISBN: 978-3-322-83447-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation